Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia

Trial Profile

Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs REGN 1979 (Primary) ; REGN 2810 (Primary)
  • Indications Acute lymphoblastic leukaemia; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2017 Planned number of patients changed from 318 to 154.
    • 16 Nov 2016 Planned number of patients changed from 154 to 318.
    • 02 May 2016 The protocol has been amended with the addition of the drug REGN1979 and addition of patients having ALL. Hence the patient no. has increased to 154 and the treatment table has been amended to include 2 arms.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top